The short version
AOD-9604 is a modified fragment of human growth hormone, rather than the whole hormone. Researchers have investigated it in metabolic experiments and human trials. This page separates a human safety report from an early animal study.
An investigational profile is not an endorsement or a finding of safety.
Names you may see
Compound names, research identifiers, brand names and informal shorthand serve different purposes.
- AOD-9604
- Entry name · The name used for this encyclopedia topic.
- AOD9604
- Recorded name variation · A name associated with this entry; check exact ingredient, modification, formulation and context.
- AOD 9604
- Recorded name variation · A name associated with this entry; check exact ingredient, modification, formulation and context.
Similar names do not establish identical ingredients, molecular variants, product quality or interchangeable preparations. A blend nickname may describe different formulas.
Things worth checking
Why do formulation conditions matter?
FDA describes sensitivity to pH, temperature, concentration and other conditions that can cause aggregation or degradation. This does not establish a universal acid-based mixing method. Ask a dispensing pharmacist about the exact formulation and any change in its appearance.
Regulatory formulation assessment · FDA · AOD-9604 assessment, printed pages 8 and 12 ↗
Questions to bring to a clinician or pharmacist
- Which findings apply to my goal and medical history?
- Could my medicines, supplements, or other compounds change the assessment?
- What monitoring, if any, would inform a decision—and what symptoms would need evaluation?
Monitoring is individual. Normal bloodwork does not establish that a compound or preparation is safe.
Delivery methods
How a compound is delivered can change the question being studied. These selected examples explain the route, purpose and evidence limits; they do not establish an appropriate route for an individual.
Oral treatment
Agency assessment of sponsor-reported trial
- Why it was studied or discussed
- Weight-loss comparison in the OPTIONS obesity trial.
- What this means for the reader
- The primary weight-loss endpoint was not met. These findings do not validate an injectable preparation.
Intravenous exposure and oral treatment
Human safety report
- Why it was studied or discussed
- Safety observations across studies in the 2013 report.
- What this means for the reader
- Different routes and durations were used. Short-term tolerability findings do not establish injectable weight-loss efficacy.
This is a selected comparison, not an exhaustive list of preparations or a guide to administering them. The clinical summaries below identify the route used in each study.
Clinical research
The selected human safety publication and the separately reported obesity trial answer different questions. A tolerability finding does not establish weight-loss benefit.
Human safety and tolerability report (2013)
Summary based on: Published full text · selected sections
- Study design
- Publication summarizing six randomized, double-blind, placebo-controlled trials, with different routes and treatment durations.
- Who was studied
- Trial groups varied; the report describes adults with obesity in its longer oral studies.
- Route and preparation
- Mixed routes across trials in this safety report; longer studies used oral treatment.
- What was compared
- AOD-9604 versus placebo. The longest described treatment period was 24 weeks using oral treatment.
- What researchers found
- The authors reported broadly similar safety findings to placebo and no significant differences in IGF-1 levels in the longer studies. Serious events occurred; investigators did not attribute them to the study treatment.
- What this leaves unanswered
- This is a safety-focused report, not proof of weight-loss benefit, absence of rare harms, or long-term safety. Its conclusions should not be extended to a different route or preparation.
- Funding context
- Two authors list affiliations with Metabolic Pharmaceuticals, the developer; independent appraisal and fuller conflict review are pending.
OPTIONS obesity trial · sponsor-reported results (2007)
Summary based on: FDA’s 2024 evidence briefing, citing sponsor reporting; PDF printed page 21
- Study design
- Randomized, double-blind, placebo-controlled trial; 24 weeks of treatment.
- Who was studied
- Adults with obesity; FDA reports 536 enrolled and 502 randomized.
- Route and preparation
- Oral treatment in the OPTIONS trial.
- What was compared
- Three oral AOD-9604 groups versus placebo, alongside supervised diet and exercise.
- What researchers found
- FDA’s summary reports no statistically significant difference from placebo for the primary weight-loss endpoint at 12 weeks.
- What this leaves unanswered
- This source is an agency evidence assessment of sponsor-reported trial results, not a complete peer-reviewed trial report. Enrollment counts differ from the 2013 safety paper. It does not establish injectable efficacy.
- Funding context
- Metabolic Pharmaceuticals developed the drug and reported the trial.
Research terms in everyday language ↗
The OPTIONS efficacy finding is drawn from FDA’s 2024 briefing, which cites sponsor reporting rather than a complete journal trial report. Independent full-trial appraisal and later research remain pending.
Read findings in the context of the exact product or preparation, the people studied, and the outcome measured. These draft profiles are starting points, rather than complete systematic reviews.
Community research
Structured community reports can help identify questions worth studying. They are considered separately from controlled studies, with their limitations kept visible.
No community reports published yet.
This profile has no published community dataset. We do not infer a trend or a benefit from missing reports.
How community research will work ↗What we will document about community advice
- The advice
- What people recommend, with dated sources and the scope of the discussions examined.
- The reasoning
- Why contributors believe it helps, without treating that explanation as an established mechanism.
- The evidence
- What supports the claim, contradicts it, or has not been tested.
- The cautions
- Possible downsides, conflicting experiences, and questions for a clinician or pharmacist.
No recommendation or community consensus is established by this framework. Descriptions of how common advice is will need documented source coverage.
A closer look
- Classification
- Modified growth-hormone fragment research
- Name variations
- Names you may see and important distinctions
- Source type
- Human safety report · not a prescribing label
- Reference jurisdiction
- United States
Interpret the source in the context of the preparation and route it discusses. A regulatory notice and a controlled clinical trial answer different questions.
Metabolic research in obese rats (2000)
Researchers reported reduced body-weight gain and changes in fat metabolism in obese Zucker rats. Reduced weight gain in rats is not a demonstrated weight-loss benefit in people.
Read the original paper ↗This first design edition reserves space for study-by-study summaries, definitions, and technical references as each profile receives editorial review.
Go to the source
Study cards identify whether the summary uses an abstract, full text, or an agency assessment. Follow the linked sources for their original context.
Source reference · Checked 7 November 2026 · Opens in a new tab
Regulatory safety context; not clinical efficacy evidence.
Sponsor disclosure cited by FDA; distinct from a peer-reviewed clinical report.
For athletes: competition rules are a separate check ↗